Nitric oxide in the pathogenesis of vascular disease

Journal of Pathology

Volumn 190, Issue 3, 2000, Pages 244-254

  Li, Huige ^a   Förstermann, Ulrich ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Atherosclerosis; Diabetes; Endothelial cells; Hypertension; Septic shock; Stroke

Indexed keywords

ARGININE; CYTOKINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; TETRAHYDROBIOPTERIN;

DISEASE ASSOCIATION; HOMEOSTASIS; HYPOTENSION; LEUKOCYTE ADHERENCE INHIBITION; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SHOCK; THROMBOCYTE AGGREGATION INHIBITION; VASCULAR DISEASE; VASODILATATION;

CARDIOVASCULAR DISEASES; DIABETIC ANGIOPATHIES; ENDOTHELIUM, VASCULAR; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS;

EID: 0342723791     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(200002)190:3<244::AID-PATH575>3.0.CO;2-8     Document Type: Review

References (184)

1. Green LC, Ruiz de Luzuriaga K, Wagner DA, et al. Nitrate biosynthesis in man. Proc Natl Acad Sci U S A 1981; 78: 7764-7768.
2. Green LC, Tannenbaum SR, Goldmann P. Nitrate synthesis in the germfree and conventional rat. Science 1981; 212: 56-58.
3. Stuehr DJ, Marietta MA. Mammalian nitrate biosynthesis: mouse macrophages produce nitrite and nitrate in response to Escherichia coli lipopolysaccharide. Proc Natl Acad Sci U S A 1985; 82: 7738-7742.
4. Iyengar R, Stuehr DJ, Marietta MA. Macrophage synthesis of nitrite, nitrate, and N-nitrosamines: precursors and role of the respiratory burst. Proc Natl Acad Sci U S A 1987; 84: 6369-6373.
5. Hibbs JB, Taintor RR, Vavrin Z. Macrophage cytotoxicity: role of L-arginine deiminase and imino nitrogen oxidation to nitrite. Science 1987; 235: 473-476.
6. Marietta MA, Yoon PS, Iyengar R, Leaf CD, Wishnok JS. Macrophage oxidation of L-arginine to nitrite and nitrate: nitric oxide is an intermediate. Biochemistry 1988; 27: 8706-8711.
7. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-376.
8. Furchgott RF, Cherry PD, Zawadzki JV, Jothianandan D. Endothelial cells as mediators of vasodilation of arteries. J Cardiovasc Pharmacol 1984; 53: 557-573.
9. Ignarro LJ, Burke TM, Wood KS, Wolin MS, Kadowitz PJ. Association between cyclic GMP accumulation and acetylcholine-elicited relaxation of bovine intrapulmonary artery. J Pharmacol Exp Ther 1984; 228: 682-690.
10. Rapoport RM, Murad F. Agonist-induced endothelium-dependent relaxation in rat thoracic aorta may be mediated through cGMP. Circ Res 1983; 52: 352-357.
11. Fiscus RR, Rapoport RM, Murad F. Endothelium-dependent and nitrovasodilator-induced activation of cyclic GMP-dependent protein kinase in rat aorta. J Cycl Nucl Prot Phosphor Res 1983; 9: 415-425.
12. Förstermann U, Mülsch A, Böhme E, Busse R. Stimulation of soluble guanylate cyclase by an acetylcholine-induced endothelium-derived factor from rabbit and canine arteries. Circ Res 1986; 58: 531-538.
13. Ignarro LJ, Harbison RG, Wood KS, Kadowitz PJ. Activation of purified soluble guanylate cyclase by endothelium-derived relaxing factor from intrapulmonary artery and vein: stimulation by acetylcholine, bradykinin and arachidonic acid. J Pharmacol Exp Ther 1986; 237: 893-900.
14. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-526.
15. Furchgott RF. Studies on relaxation of rabbit aorta by sodium nitrite: the basis for the proposal that the acid-activatable inhibitory factor from bovine retractor penis is inorganic nitrite and the endothelium-derived relaxing factor is nitric oxide. In Vasodilatation: Vascular Smooth Muscle, Peptides, Autonomic Nerves, and Endothelium, Vanhoutte P. (ed.). Raven Press: New York, 1988; 401-414.
16. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A 1987; 84: 9265-9269.
17. Schmidt HHHW, Nau H, Wittfoht W, et al. Arginine is a physiological precursor of endothelium-derived nitric oxide. Eur J Pharmacol 1988; 154: 213-216.
18. Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988; 333: 664-666.
19. Knowles RG, Palacios M, Palmer RM, Moncada S. Formation of nitric oxide from L-arginine in the central nervous system: a transduction mechanism for stimulation of the soluble guanylate cyclase. Proc Natl Acad Sci U S A 1989; 86: 5159-5162.
20. Förstermann U, Gorsky LD, Pollock JS, et al. Hormone-induced biosynthesis of endothelium-derived relaxing factor/ nitric oxide-like material in N1E-115 neuroblastoma cells requires calcium and calmodulin. Mol Pharmacol 1990; 38: 7-13.
21. Garthwaite J, Charles SL, Chess-Williams R. Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain. Nature 1998; 336: 385-388.
22. Stuehr DJ, Cho HJ, Kwon NS, Weise MF, Nathan CF. Purification and characterization of the cytokine-induced macrophage nitric oxide synthase: an FAD- and FMN-containing flavoprotein. Proc Natl Acad Sci U S A 1991; 88: 7773-7777.
23. Pollock JS, Förstermann U, Mitchell JA, et al. Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells. Proc Natl Acad Sci U S A 1991; 88: 10480-10484.
24. Mayer B, John M, Heinzel B, et al. Brain nitric oxide synthase is a biopterin- and flavin-containing multi-functional oxidoreductase. FEBS Lett 1991; 288: 187-191.
25. Hevel JM, Marletta MA. Macrophage nitric oxide synthase: relationship between enzyme-bound tetrahydrobiopterin and synthase activity. Biochemistry 1992; 31: 7160-7165.
26. Rapoport RM, Draznin MB, Murad F. Endothelium-dependent relaxation in rat aorta may be mediated through cyclic GMP-dependent protein phosphorylation. Nature 1983; 306: 174-176.
27. Halbrügge T, Lütsch K, Thyen A, Graefe KH. Role of nitric oxide formation in the regulation of haemodynamics and the release of noradrenaline and adrenaline. Naunyn-Schmiedebergs Arch Pharmakol 1991; 344: 720-727.
28. G-methylarginine, an inhibitor of endothelium-derived nitric oxide synthesis, is a potent pressor agent in the guinea pig: does nitric oxide regulate blood pressure in vivo? Biochem Biophys Res Commun 1989; 160: 881-886.
29. Rees DD, Palmer RM, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci U S A 1989; 86: 3375-3378.
30. Gardiner SM, Compton AM, Bennett T, Palmer RM, Moncada S. Control of regional blood flow by endothelium-derived nitric oxide. Hypertension 1990; 15: 486-492.
31. G-monomethyl-L-arginine (NMA) restores arterial blood pressure but reduces cardiac output in a canine model of endotoxic shock. Biochem Biophys Res Commun 1991; 178: 1135-1140.
32. Tresham JJ, Dusting GJ, Coghlan JP, Whitworth JA. Haemodynamic and hormonal effects of N-nitro-L-arginine, an inhibitor of nitric oxide biosynthesis, in sheep. Clin Exp Pharmacol Physiol 1991; 18: 327-330.
33. Richard V, Berdcaux A, la Rochelle CD, Giudicelli JF. Regional coronary haemodynamic effects of two inhibitors of nitric oxide synthesis in anaesthetized, open-chest dogs. Br J Pharmacol 1991; 104: 59-64.
34. Persson MG, Wiklund NP, Gustafsson LE. Nitric oxide requirement for vasomotor nerve-induced vasodilatation and modulation of resting blood flow in muscle microcirculation. Acta Physiol Scand 1991; 141: 49-56.
35. Mügge A, Lopez JA, Piegors DJ, Breese KR, Heistad DD. Acetylcholine-induced vasodilatation in rabbit hindlimb in vivo is not inhibited by analogues of L-arginine. Am J Physiol 1991; 260: H242-H247.
36. Huang PL, Huang ZH, Mashimo H, et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 1995; 377: 239-242.
37. Radomski MW, Palmer RM, Moncada S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol 1987; 92: 639-646.
38. Radomski MW, Palmer RM, Moncada S. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun 1987; 148: 1482-1489.
39. Alheid U, Frölich JC, Förstermann U. Endothelium-derived relaxing factor from cultured human endothelial cells inhibits aggregation of human platelets. Thromb Res 1987; 47: 561-571.
40. Busse R, Lückhoff A, Bassenge E. Endothelium-derived relaxant factor inhibits platelet activation. Naunyn-Schmiedebergs Arch Pharmakol 1987; 336: 566-571.
41. Zeiher AM, Fisslthaler B, Schray Utz B, Busse R. Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. Circ Res 1995; 76: 980-986.
42. Tsao PS, Wang B, Buitrago R, Shyy JY, Cooke JP. Nitric oxide regulates monocyte chemotactic protein-1. Circulation 1997; 96: 934-940.
43. Arndt H, Smith CW, Granger DN. Leukocyte endothelial cell adhesion in spontaneously hypertensive and normotensive rats. Hypertension 1993; 21: 667-673.
44. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A 1991; 88: 4651-4655.
45. Davenpeck KL, Gauthier TW, Lefer AM. Inhibition of endothelial-derived nitric oxide promotes P-selectin expression and actions in the rat microcirculation. Gastroenterology 1994; 107: 1050-1058.
46. Gauthier TW, Scalia R, Murohara T, Guo JP, Lefer AM. Nitric oxide protects against leukocyte endothelium interactions in the early stages of hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995; 15: 1652-1659.
47. De Caterina R, Libby P, Peng HB, et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995; 96: 60-68.
48. Tsao PS, Buitrago R, Chan JR, Cooke JP. Fluid flow inhibits endothelial adhesiveness. Nitric oxide and transcriptional regulation of VCAM-1. Circulation 1996; 94: 1682-1689.
49. Cardona-Sanclemente LE, Born GV. Effect of inhibition of nitric oxide synthesis on the uptake of LDL and fibrinogen by arterial walls and other organs of the rat. Br J Pharmacol 1995; 114: 1490-1494.
50. Draijer R, Atsma DE, van der Laarse A, van Hinsbergh VW. cGMP and nitric oxide modulate thrombin-induced endothelial permeability. Regulation via different pathways in human aortic and umbilical vein endothelial cells. Circ Res 1995; 76: 199-208.
51. Hogg N, Kalyanaraman B, Joseph J, Struck A, Parthasarathy S. Inhibition of low-density lipoprotein oxidation by nitric oxide. Potential role in atherogenesis. FEBS Lett 1993; 334: 170-174.
52. Goss SP, Hogg N, Kalyanaraman B. The effect of nitric oxide release rates on the oxidation of human low density lipoprotein. J Biol Chem 1997; 272: 21647-21653.
53. 2+ -induced LDL oxidation by nitric oxide: a study using donors with different half-time of NO release. Biochem Biophys Res Commun 1996; 220: 306-309.
54. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83: 1774-1777.
55. Nakaki T, Nakayama M, Kato R. Inhibition by nitric oxide and nitric oxide-producing vasodilators of DNA synthesis in vascular smooth muscle cells. Eur J Pharmacol 1990; 189: 347 353.
56. Nunokawa Y, Tanaka S. Interferon-gamma inhibits proliferation of rat vascular smooth muscle cells by nitric oxide generation. Biochem Biophys Res Commun 1992; 188: 409-415.
57. Hogan M, Cerami A, Bucala R. Advanced glycosylation end products block the antiproliferative effect of nitric oxide. Role in the vascular and renal complications of diabetes mellitus. J Clin Invest 1992; 90: 1110-1115.
58. Southgate K, Newby AC. Serum-induced proliferation of rabbit aortic smooth muscle cells from the contractile state is inhibited by 8-Br-cAMP but not 8-Br-cGMP. Atherosclerosis 1990; 82: 113-123.
59. Dubey RK, Jackson EK, Lüscher TF. Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cell. Role of cyclic-nucleotides and angiotensin-1 receptors. J Clin Invest 1995; 96: 141-149.
60. Cayatte AJ, Palacino JJ, Horten K, Cohen RA. Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler Thromb 1994; 14: 753-759.
61. Togashi H, Sakuma I, Yoshioka M, et al. A central nervous system action of nitric oxide in blood pressure regulation. J Pharmacol Exp Ther 1992; 262: 343-347.
62. G-methyl-L-arginine, an inhibitor of L-arginine-derived nitric oxide synthesis, stimulates renal sympathetic nerve activity in vivo. A role for nitric oxide in the central regulation of sympathetic tone? Circ Res 1992; 70: 607-611.
63. Elkarib AO, Sheng JJ, Betz AL, Malvin RL. The central effects of a nitric oxide synthase inhibitor (N-omega-nitro-L-arginine) on blood pressure and plasma renin. Clin Exp Hypertension 1993; 15: 819-832.
64. Iadecola C, Zhang F, Xu X. Role of nitric oxide synthase-containing vascular nerves in cerebrovasodilation elicited from cerebellum. Am J Physiol 1993; 264: R738-R746.
65. Bult H, Boeckxstaens GE, Pelckmans PA, Jordaens FH, Van Maercke YM, Herman AG. Nitric oxide as an inhibitory nonadrenergic non-cholinergic neurotransmitter. Nature 1990; 345: 346-347.
66. Li CG, Rand MJ. Evidence that part of the NANC relaxant response of guinea-pig trachea to electricl field stimulation is mediated by nitric oxide. Br J Pharmacol 1991; 102: 91-94.
67. Toda N, Okamura T. Reciprocal regulation by putatively nitroxidergic and adrenergic nerves of monkey and dog temporal arterial tone. Am J Physiol 1991; 261: H1740-H1745.
68. Cederqvist B, Wiklund NP, Persson MG, Gustafsson LE. Modulation of neuroeffector transmission in the guinea pig pulmonary artery by endogenous nitric oxide. Neurosci Lett 1991; 127: 67-69.
69. Liu SF, Crawley DE, Rohde JA, Evans TW, Barnes PJ. Role of nitric oxide and guanosine 3′,5′-cyclic monophosphate in mediating nonadrenergic, noncholinergic relaxation in guinea-pig pulmonary arteries. Br J Pharmacol 1992; 107: 861-866.
70. Toda N, Okamura T. Mechanism of neurally induced monkey mesenteric artery relaxation and contraction. Hypertension 1992; 19: 161-166.
71. Chen FY, Lee TJ. Role of nitric oxide in neurogenic vasodilation of porcine cerebral artery. J Pharmacol Exp Ther 1993; 265: 339-345.
72. Yoshida K, Okamura T, Kimura H, Bredt DS, Snyder SH, Toda N. Nitric oxide synthase-immunoreactive nerve fibers in dog cerebral and peripheral arteries. Brain Res 1993; 629: 67-72.
73. Huang PL, Dawson TM, Bredt DS, Snyder SH, Fishman MC. Targeted disruption of the neuronal nitric oxide synthase gene. Cell 1993; 75: 1273-1286.
74. Stroes ES, Koomans HA, de Bruin TW, Rabelink TJ. Vascular function in the forearm of hypercholesterolaemic patients off and or lipid-lowering medication. Lancet 1995; 346: 467-471.
75. Williams SB, Cusco JA, Roddy MA, Johnstone MT, Creager MA. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1996; 27: 567-574.
76. Panza JA, Garcia CE, Kilcoyne CM, Quyyumi AA, Cannon RO, 3rd. Impaired endothelium-dependent vasodilation in patients with essential hypertension. Evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. Circulation 1995; 91: 1732-1738.
77. Heitzer T, Just H, Munzel T. Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. Circulation 1996; 94: 6-9.
78. Förstermann U, Mügge A, Alheid U, Haverich A, Frölich JC. Selective attenuation of endothelium-mediated vasodilation in atherosclerotic human coronary arteries. Circ Res 1988; 62: 185-190.
79. Minor RJ, Myers PR, Guerra RJ, Bates JN, Harrison DG. Diet-induced atherosclerosis increases the release of nitrogen oxides from rabbit aorta. J Clin Invest 1990; 86: 2109-2116.
80. Ludmer PL, Selwyn AP, Shook TL, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986; 315: 1046-1051.
81. Mügge A, Elwell JH, Peterson TE, Hofmeyer TG, Heistad DD, Harrison DG. Chronic treatment with polyethylene-glycolated superoxide dismutase partially restores endothelium-dependent vascular relaxations in cholesterol-fed rabbits. Circ Res 1991; 69: 1293-1300.
82. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993; 91: 2546-2551.
83. Pritchard KA Jr, Groszek L, Smalley DM, et al. Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ Res 1995; 77: 510-518.
84. Wever RMF, van Dam T, van Rijn HJ, de Groot F, Rabelink TJ. Tetrahydrobiopterin regulates superoxide and nitric oxide generation by recombinant endothelial nitric oxide synthase. Biochem Biophys Res Commun 1997; 237: 340-344.
85. Miller RT, Martasek P, Roman LJ, Nishimura JS, Masters BS. Involvement of the reductase domain of neuronal nitric oxide synthase in superoxide anion production. Biochemistry 1997; 36: 15277-15284.
86. Klatt P, Pfeiffer S, List BM, et al. Characterization of heme-deficient neuronal nitric-oxide synthase reveals a role for heme in subunit dimerization and binding of the amino acid substrate and tetrahydrobiopterin. J Biol Chem 1996; 271: 7336-7342.
87. Venema RC, Ju H, Zou R, Ryan JW, Venema VJ. Subunit interactions of endothelial nitric-oxide synthase. Comparisons to the neuronal and inducible nitric-oxide synthase isoforms. J Biol Chem 1997; 272: 1276-1282.
88. Warnholtz A, Nickenig G, Schulz E, et al. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation 1999; 99: 2027-2033.
89. Buttery LD, Springall DR, Chester AH, et al. Inducible nitric oxide synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite. Lab Invest 1996; 75: 77-85.
90. Ma XL, Lopez BL, Liu GL, et al. Hypercholesterolemia impairs a detoxification mechanism against peroxynitrite and renders the vascular tissue more susceptible to oxidative injury. Circ Res 1997; 80: 894-901.
91. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 1996; 271: C1424-C1437.
92. Kanazawa K, Kawashima S, Mikami S, et al. Endothelial constitutive nitric oxide synthase protein and mRNA increased in rabbit atherosclerotic aorta despite impaired endothelium-dependent vascular relaxation. Am J Pathol 1996; 148: 1949-1956.
93. Hirata K, Miki N, Kuroda Y, Sakoda T, Kawashima S, Yokoyama M. Low concentration of oxidized low-density lipoprotein and lysophosphatidylcholine upregulate constitutive nitric oxide synthase mRNA expression in bovine aortic endothelial cells. Circ Res 1995; 76: 958-962.
94. Liao JK, Shin WS, Lee WY, Clark SL. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem 1995; 270: 319-324.
95. Vidal F, Colome C, Martinez Gonzalez J, Badimon L. Atherogenic concentrations of native low-density lipoproteins down-regulate nitric-oxide-synthase mRNA and protein levels in endothelial cells. Eur J Biochem 1998; 252: 378-384.
96. Ramasamy S, Parthasarathy S, Harrison DG. Regulation of endothelial nitric oxide synthase gene expression by oxidized linoleic acid. J Lipid Res 1998; 39: 268-276.
97. Oemar BS, Tschudi MR, Godoy N, Brovkovich V, Malinski T, Lüscher TF. Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis. Circulation 1998; 97; 2494-2498.
98. Yoshizumi M, Perrella MA, Burnett JC Jr, Lee ME. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res 1993; 73: 205-209.
99. Alonso J, Sanchez de Miguel L, Monton M, Casado S, Lopez Farre A. Endothelial cytosolic proteins bind to the 3′ untranslated region of endothelial nitric oxide synthase mRNA: regulation by tumor necrosis factor alpha. Mol Cell Biol 1997; 17: 5719-5726.
100. Miyazaki H, Matsuoka H, Cooke JP, et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999; 99: 1141-1146.
101. Bode-Böger SM, Boger RH, Kienke S, Junker W, Frölich JC. Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits. Biochem Biophys Res Commun 1996; 219: 598-603.
102. Böger RH, Bode-Böger SM, Thiele W, Junker W, Alexander K, Frölich JC. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease [see comments]. Circulation 1997; 95: 2068-2074.
103. Cooke JP, Tsao PS. Arginine: a new therapy for atherosclerosis? Circulation 1997; 95: 311-312.
104. Calver A, Collier J, Leone A, Moncada S, Vallance P. Effect of local intra-arterial asymmetric dimethylarginine (ADMA) on the forearm arteriolar bed of healthy volunteers. J Hum Hypertens 1993; 7: 193-194.
105. Cooke JP, Andon NA, Girerd XJ, Hirsch AT, Creager MA. Arginine restores cholinergic relaxation of hypercholesterolemic rabbit thoracic aorta. Circulation 1991; 83: 1057-1062.
106. Drexler H, Fischell TA, Pinto FJ, et al. Effect of L-arginine on coronary endothelial function in cardiac transplant recipients. Relation to vessel wall morphology. Circulation 1994; 89: 1615-1623.
107. Tsao PS, Theilmeier G, Singer AH, Leung LL, Cooke JP. L-arginine attenuates platelet reactivity in hypercholesterolemic rabbits. Arterioscler Thromb 1994; 14: 1529-1533.
108. Wolf A, Zalpour C, Theilmeier G, et al. Dietary L-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans. J Am Coll Cardiol 1997; 29: 479-485.
109. Tsao PS, McEvoy LM, Drexler H, Butcher EC, Cooke JP. Enhanced endothelial adhesiveness in hypercholesterolemia is attenuated by L-arginine. Circulation 1994; 89: 2176-2182.
110. Adams MR, Jessup W, Hailstones D, Celermajer DS. L-arginine reduces human monocyte adhesion to vascular endothelium and endothelial expression of cell adhesion molecules. Circulation 1997; 95: 662-668.
111. Theilmeier G, Chan JR, Zalpour C, et al. Adhesiveness of mononuclear cells in hypercholesterolemic humans is normalized by dietary L-arginine. Arterioscler Thromb Vasc Biol 1997; 17: 3557-3564.
112. Cooke JP, Singer AH, Tsao P, Zera P, Rowan RA, Billingham ME. Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J Clin Invest 1992; 90: 1168-1172.
113. Candipan RC, Wang BY, Buitrago R, Tsao PS, Cooke JP. Regression or progression. Dependency on vascular nitric oxide. Arterioscler Thromb Vasc Biol 1996; 16: 44-50.
114. Böger RH, Bode-Böger SM, Brandes RP, et al. Dietary L-arginine reduces the progression of atherosclerosis in cholesterol-fed rabbits: comparison with lovastatin. Circulation 1997; 96: 1282-1290.
115. Wang BY, Ho HKV, Lin PS, et al. Regression of atherosclerosis - Role of nitric oxide and apoptosis. Circulation 1999; 99: 1236-1241.
116. Baydoun AR, Emery PW, Pearson JD, Mann GE. Substrate-dependent regulation of intracellular amino acid concentrations in cultured bovine aortic endothelial cells. Biochem Biophys Res Commun 1990; 173: 940-948.
117. Gold ME, Bush PA, Ignarro LJ. Depletion of arterial L-arginine causes reversible tolerance to endothelium-dependent relaxation. Biochem Biophys Res Commun 1989; 164: 714-721.
118. G-monomethyl-L-arginine to L-citrulline and subsequently to L-arginine. Biochem Biophys Res Commun 1990; 167: 1037-1043.
119. Giugliano D, Marfella R, Verrazzo G, Acampora R, Coppola L, Cozzolino D, D'Onofrio F. The vascular effects of L-arginine in humans. The role of endogenous insulin. J Clin Invest 1997; 99: 433-438.
120. Higman DJ, Strachan AM, Buttery L, et al. Smoking impairs the activity of endothelial nitric oxide synthase in saphenous vein. Arterioscler Thromb Vasc Biol 1996; 16: 546-552.
121. Stroes E, Kastelein J, Cosentino F, et al. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest 1997; 99: 41-46.
122. Werner ER, Pitters E, Schmidt K, Wachter H, Werner Felmayer G, Mayer B. Identification of the 4-amino analogue of tetrahydrobiopterin as a dihydropteridine reductase inhibitor and a potent pteridine antagonist of rat neuronal nitric oxide synthase. Biochem J 1996; 320: 193-196.
123. Witteveen CF, Giovanelli J, Kaufman S. Reduction of quinonoid dihydrobiopterin to tetrahydrobiopterin by nitric oxide synthase. J Biol Chem 1996; 271: 4143-4147.
124. Mügge A, Brandes RP, Böger RH, et al. Vascular release of superoxide radicals is enhanced in hypercholesterolemic rabbits. J Cardiovasc Pharmacol 1994; 24: 994-998.
125. Wever RM, Lüscher TF, Cosentino F, Rabelink TJ. Atherosclerosis and the two faces of endothelial nitric oxide synthase. Circulation 1998; 97: 108-112.
126. Ting HH, Timimi FK, Haley EA, Roddy MA, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in forearm resistance vessels of humans with hypercholesterolemia. Circulation 1997; 95: 2617-2622.
127. Lüscher TF, Tanner FC, Tschudi MR, Noll G. Endothelial dysfunction in coronary artery disease. Annu Rev Med 1993; 44: 395-418.
128. Pieper GM, Peltier BA. Amelioration by L-arginine of a dysfunctional arginine/nitric oxide pathway in diabetic endothelium. J Cardiovasc Pharmacol 1995; 25: 397-403.
129. Pieper GM. Acute amelioration of diabetic endothelial dysfunction with a derivative of the nitric oxide synthase cofactor, tetrahydrobiopterin. J Cardiovasc Pharmacol 1997; 29: 8-15.
130. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318: 1315-1321.
131. Greene DA, Lattimer SA, Sima AA. Sorbitol, phosphoinositides, and sodium potassium-ATPase in the pathogenesis of diabetic complications. N Engl J Med 1987; 316: 599-606.
132. King GL, Kunisaki M, Nishio Y, Inoguchi T, Shiba T, Xia P. Biochemical and molecular mechanisms in the development of diabetic vascular complications. Diabetes 1996; 45: S105-S108.
133. Ishii H, Koya D, King GL. Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus. J Mol Med 1998; 76: 21-31.
134. Tesfamariam B, Brown ML, Cohen RA. Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C. J Clin Invest 1991; 87: 1643-1648.
135. Ishii H, Jirousek MR, Koya D, et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996; 272: 728-731.
136. Hirata K, Kuroda R, Sakoda T, et al. Inhibition of endothelial nitric oxide synthase activity by protein kinase C. Hypertension 1995; 25: 180-185.
137. Cosentino F, Hishikawa K, Katusic ZS, Luscher TF. High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation 1997; 96: 25-28.
138. Honing MLH, Morrison PJ, Banga JD, Stroes ESG, Rabelink TJ. Nitric oxide availability in diabetes mellitus. Diabetes Metab Rev 1998; 14: 241-249.
139. Linder L, Kiowski W, Buhler FR, Luscher TF. Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension. Circulation 1990; 81: 1762-1767.
140. Taddei S, Virdis A, Ghiadoni L, Salvetti A. Endothelial dysfunction in hypertension: fact or fancy? J Cardiovasc Pharmacol 1998; 32: S41-S47.
141. Rizzoni D, Porteri E, Castellano M, et al. Vascular hypertrophy and remodeling in secondary hypertension. Hypertension 1996; 28: 785-790.
142. Rudic RD, Shesely EG, Maeda N, Smithies O, Segal SS, Sessa WC. Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. J Clin Invest 1998; 101: 731-736.
143. Uwabo J, Soma M, Nakayama T, Kanmatsuse K. Association of a variable number of tandem repeats in the endothelial constitutive nitric oxide synthase gene with essential hypertension in Japanese. Am J Hypertens 1998; 11: 125-128.
144. Tsukada T, Yokoyama K, Arai T, et al. Evidence of association of the ecNOS gene polymorphism with plasma NO metabolite levels in humans. Biochem Biophys Res Commun 1998; 245: 190-193.
145. Lacolley P, Gautier S, Poirier O, Pannier B, Cambien F, Benetos A. Nitric oxide synthase gene polymorphisms, blood pressure and aortic stiffness in normotensive and hypertensive subjects. J Hypertens 1998; 16: 31-35.
146. Miyamoto Y, Saito Y, Kajiyama N, et al. Endothelial nitric-oxide synthase gene is positively associated with essential hypertension. Hypertension 1998; 32: 3-8.
147. Tschudi MR, Mesaros S, Lüscher TF, Malinski T. Direct in situ measurement of nitric oxide in mesenteric resistance arteries. Increased decomposition by superoxide in hypertension. Hypertension 1996; 27: 32-35.
148. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Cyclooxygenase inhibition restores nitric oxide activity in essential hypertension. Hypertension 1997; 29: 274-279.
149. Heitzer T, Wenzel U, Hink U, et al. Increased NAD(P)H oxidase-mediated superoxide production in renovascular hypertension: evidence for an involvement of protein kinase C. Kidney Int 1999; 55: 252-260.
150. Cosentino F, Lüscher TF. Tetrahydrobiopterin and endothelial function. Eur Heart J 1998; 19: G3-G8.
151. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation 1998; 97: 2222-2229.
152. Schiffrin EL, Deng LY. Structure and function of resistance arteries of hypertensive patients treated with a beta-blocker or a calcium channel antagonist. J Hypertens 1996; 14: 1247-1255.
153. Taddei S, Virdis A, Ghiadoni L, Uleri S, Magagna A, Salvetti A. Lacidipine restores endothelium-dependent vasodilation in essential hypertensive patients. Hypertension 1997; 30: 1606-1612.
154. + channels in rat aorta and brain microvascular endothelial cells. Am J Physiol 1993; 265: C812-C821.
155. Salameh A, Schomecker G, Breitkopf K, Dhein S, Klaus W. The effect of the calcium-antagonist nitrendipine on intracellular calcium concentration in endothelial cells. Br J Pharmacol 1996; 118: 1899-1904.
156. Ding Y, Vaziri ND. Calcium channel blockade enhances nitric oxide synthase expression by cultured endothelial cells. Hypertension 1998; 32: 718-723.
157. Mak IT, Boehme P, Weglicki WB. Antioxidant effects of calcium channel blockers against free radical injury in endothelial cells. Correlation of protection with preservation of glutathione levels. Circ Res 1992; 70: 1099-1103.
158. Lupo E, Locher R, Weisser B, Vetter W. In vitro antioxidant activity of calcium antagonists against LDL oxidation compared with alpha-tocopherol. Biochem Biophys Res Commun 1994; 203: 1803-1808.
159. Calo L, Davis PA, Milani M, et al. Increased endothelial nitric oxide synthase mRNA level in Bartter's and Gitelman's syndrome. Relationship to vascular reactivity. Clin Nephrol 1999; 51: 12-17.
160. 3 and cyclic guanosine monophosphate levels in patients with Bartter's syndrome: relationship to vascular reactivity. Am J Kidney Dis 1996; 27: 784-789.
161. Garthwaite J. Glutamate, nitric oxide and cell-cell signalling in the nervous system. Trends Neurosci 1991; 14: 60-67.
162. Dawson VL, Dawson TM, London ED, Bredt DS, Snyder SH. Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc Natl Acad Sci USA 1991; 88: 6368-6371.
163. Huang ZH, Huang PL, Panahian N, Dalkara T, Fishman MC, Moskowitz MA. Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase. Science 1994; 265: 1883-1885.
164. Nowicki JP, Duval D, Poignet H, Scatton B. Nitric oxide mediates neuronal death after focal cerebral ischemia in the mouse. Eur J Pharmacol 1991; 204: 339-340.
165. Stamler JS. Redox signalling: nitrosylation and related target interactions of nitric oxide. Cell 1994; 78: 931-936.
166. Iadecola C, Zhang FY, Casey R, Nagayama M, Rose ME. Delayed reduction of ischemic brain injury and neurological deficits in mice lacking the inducible nitric oxide synthase gene. J Neurosci 1997; 17: 9157-9164.
167. Sancesario G, Iannone M, Morello M, Nistico G, Bernardi G. Nitric oxide inhibition aggravates ischemic damage of hippocampal but not of NADPH neurons in gerbils. Stroke 1994; 25: 436-443.
168. Hamada J, Greenberg JH, Croul S, Dawson TM, Reivich M. Effects of central inhibition of nitric oxide synthase on focal cerebral ischemia in rats. J Cereb Blood Flow Metab 1995; 15: 779-786.
169. Yamamoto S, Golanov EV, Berger SB, Reis DJ. Inhibition of nitric oxide synthesis increases focal ischemic infarction in rat. J Cereb Blood Flow Metab 1992; 12: 717-726.
170. Marks KA, Mallard CE, Roberts I, Williams CE, Gluckman PD, Edwards AD. Nitric oxide synthase inhibition attenuates delayed vasodilation and increases injury after cerebral ischemia in fetal sheep. Pediatr Res 1996; 40: 185-191.
171. Stagliano NE, Dietrich WD, Prado R, Green EJ, Busto R. The role of nitric oxide in the pathophysiology of thromboembolic stroke in the rat. Brain Res 1997; 759: 32-40.
172. Huang Z, Huang PL, Ma J, et al. Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-L-arginine. J Cereb Blood Flow Metab 1996; 16: 981-987.
173. Stagliano NE, Zhao WZ, Prado R, Dewanjee MK, Ginsberg MD, Dietrich WD. The effect of nitric oxide synthase inhibition on acute platelet accumulation and hemodynamic depression in a rat model of thromboembolic stroke. J Cereb Blood Flow Metab 1997; 17: 1182-1190.
174. Lefer AM, Lefer DJ. Pharmacology of the endothelium in ischemia reperfusion and circulatory shock. Annu Rev Pharmacol Toxicol 1993; 33: 71-90.
175. Samdani AF, Dawson TM, Dawson VL. Nitric oxide synthase in models of focal ischemia. Stroke 1997; 28: 1283-1288.
176. Titheradge MA. Nitric oxide in septic shock. Biochim Biophys Acta 1999; 1141: 437-455.
177. Kilbourn RG, Traber DL, Szabo C. Nitric oxide and shock. Dis Mon 1997; 43: 277-348.
178. Busse R, Mülsch A. Induction of nitric oxide synthase by cytokines in vascular smooth muscle cells. FEBS Lett 1990; 275: 87-90.
179. G-methyl-L-arginine, an inhibitor of nitric oxide synthesis. Biochem Biophys Res Commun 1990; 172: 1132-1138.
180. Petros A, Bennett D, Vallance P. Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet 1991; 338: 1557-1558.
181. MacMicking JD, Nathan C, Hom G, et al. Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell 1995; 81: 641-650.
182. Szabo C, Thiemermann C, Wu CC. Perretti M, Vane JR. Attenuation of the induction of nitric oxide synthase by endogenous glucocorticoids accounts for endotoxin tolerance in vivo. Proc Natl Acad Sci USA 1994; 91: 271-275.
183. Thiemermann C. Nitric oxide and septic shock. Gen Pharmacol 1997; 29: 159-166.
184. 2+-independent nitric oxide synthase in the myocardium. Br J Pharmacol 1992; 105: 575-580.